12
Participants
Start Date
April 14, 2022
Primary Completion Date
October 14, 2024
Study Completion Date
February 1, 2026
MSLN STAR-T cells
Patients with advanced MSLN-positive solid tumors will be recruited, and autologous-derived MSLN-STAR-T cells will be infused intravenously at escalating doses of 1×10\^7-1×10\^8 MSLN-STAR-T cells. The CAR-T ratio will be monitored at predetermined times (day 0, day 4, day 7, day 10, day 14, day 28).
Peking University
OTHER